Physician profile
Michael Dolchin
NPI 1205872009
$1,884.10
in general payments reported to CMS, 2019-2025
11 companies · $43.68 in 2025
The $43.68 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $177 · 2021: $318 · 2022: $108 · 2023: $148 · 2024: $533 · 2025: $43.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $781.76 | 2019-2021 | |
| Novo Nordisk INC | $214.02 | 2023-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $192.29 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Heartflow, INC. | $164.34 | 2024-2025 | |
| Amgen INC. | $146.01 | 2022-2024 | Krystexxa, Otezla, Repatha |
| Edwards Lifesciences Corporation | $125.00 | 2019 | |
| Intuitive Surgical, INC. | $109.92 | 2024 | |
| Biosense Webster, INC. | $59.33 | 2023 | Carto 3 |
| Glaxosmithkline, LLC. | $48.78 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $25.00 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $17.65 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dolchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.